Clinical nutrition (Edinburgh, Scotland) · 2002
The local vascular tolerance to an intravenous infusion of a concentrated glutamine solution in ICU patients.
Клиническое исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Berg A, Forsberg E, Wernerman J
Аннотация
BACKGROUND AND AIMS: The beneficial effects of glutamine is well-documented in ICU patients. However, the documentation and control of enteral administration of glutamine is still insufficient. As an adjunct to enteral nutrition, a concentrated dipeptide solution may be given in a central venous line, but administration via a peripheral vein would be preferable. Therefore, we systematically evaluated local vascular tolerance following a concentrated dipeptide infusion in ICU-patients.
METHODS: ICU-patients (n=20) were randomized to receive a 20% alanyl-glutamine infusion of 0.5 g/kg or placebo during 4 h in a peripheral vein on 3 consecutive days. Local tolerance was evaluated clinically, by Maddox score, and ultrasonically before the infusion and on days 1, 4 and 8 after the infusion.
RESULTS: In the study, 56 out of 60 (93%) planned infusions were administered and 157 out of 168 (93%) clinical evaluations were successfully performed. The ultrasonic evaluation revealed that the utilized veins had a diameter of 2.15+/-0.8 mm (range, 1.0--4.4 mm). There were no signs of thrombophlebitis in any single vein.
CONCLUSION: Administration of a glutamine-containing dipeptide concentrate (20%) by peripheral veins is safe in terms of local tolerance, if a strict protocol is adapted for this purpose is used.
METHODS: ICU-patients (n=20) were randomized to receive a 20% alanyl-glutamine infusion of 0.5 g/kg or placebo during 4 h in a peripheral vein on 3 consecutive days. Local tolerance was evaluated clinically, by Maddox score, and ultrasonically before the infusion and on days 1, 4 and 8 after the infusion.
RESULTS: In the study, 56 out of 60 (93%) planned infusions were administered and 157 out of 168 (93%) clinical evaluations were successfully performed. The ultrasonic evaluation revealed that the utilized veins had a diameter of 2.15+/-0.8 mm (range, 1.0--4.4 mm). There were no signs of thrombophlebitis in any single vein.
CONCLUSION: Administration of a glutamine-containing dipeptide concentrate (20%) by peripheral veins is safe in terms of local tolerance, if a strict protocol is adapted for this purpose is used.